Mast Therapeutics, Inc. (MSTX)

[Live42Day]

Interesting post on the ANX Yahoo board (I didn't realize that the revenue potential for Adventrx's lead drug ANX-514 was so huge):

http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks_A/threadview?m=ms&bn=1150&tid=42618&mid=42619&tof=1&rt=2&frt=2&off=1

While ANX-514 is not the only pending generic equivalent of Taxotere, the market for this drug is huge. Currently, the entire taxane market is worth about $2 billion. It is projected that sales will peak at $2.6 billion in 2010 and will drop to around $2.4 billion by 2015. ANX's pharmacokinetic data from their bioequivalence study of ANX-514 is still on track to be announced this quarter. per their 2/10 PR:

From Adventrx's February 10th PR:

SAN DIEGO, Feb. 10 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Alternext US: ANX) announced today that it has received written indications of interest from numerous companies representing a range of strategic transactions. The Company currently is evaluating all proposals and options. In December 2008, the Company announced that it was exploring a range of strategic options, including the sale or disposition of one or more of its product candidate programs, a strategic business merger and other transactions that maximize the value of the Company's assets.

"We are pleased with the number and breadth of opportunities presented to us and are currently negotiating with interested parties," stated Brian M. Culley, Chief Business Officer of ADVENTRX. "In order to provide sufficient flexibility to consummate a transaction on appropriate terms, we continue to curtail our spending. While this may impact the timelines of our regulatory filings, it is likely that a future partner would make the final decision on the timing of each NDA submission. However, we still remain on track to announce pharmacokinetic data from our bioequivalence study of ANX-514 in the second quarter."

With the sales potential for ANX-514 and ANX-530 (which already demonstrated Equivalent Pharmacokinetics to Navelbine(R) in a
Registrational Bioequivalence Clinical Study completed last year), ANX Mgmt should have no problem finding a strategic partner or someone looking to pay a hefty premium (to todays pps) as a buyout offer for ANX, in the near future (based on the revenue potential once these 2 drugs obtain FDA approval). AJMHO

ANX is a steal down here @ .13. I have to believe that ANX has buyout offers on the table for at least .50/share.

IMO, that's a bargain for one of the big boys looking to get a piece of the $2.6 billion Taxane market.

I am expecting some very good news real soon out of ANX. gltu